Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03535194 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,484
- Enrollment target
NCT03535194 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,484 participants.
The verdict
NCT03535194, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,484 participants
- Enrollment target
Study Summary
The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG Mirikizumab
- DRUG Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,484 participants |
| Start Date | 2018-06-26 |
| Est. Completion | 2020-06-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03535194
The ClinicalTrials.gov registry entry for NCT03535194 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03535194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03535194 about?
NCT03535194 is a clinical study titled "A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)". The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
What is the current status of trial NCT03535194?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,484 participants. The study started on 2018-06-26. Estimated completion is 2020-06-03.
What interventions are being tested in trial NCT03535194?
The interventions under investigation include: Placebo (DRUG), Mirikizumab (DRUG), Secukinumab (DRUG).
Who is sponsoring clinical trial NCT03535194?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.